Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Our AI ranks Revvity, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Revvity, Inc. is a large-cap company with a market capitalization of $17.30B. It ranks number 5 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for RVTY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RVTY included.
Follow RVTY free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
| Metric | RVTY | Rank |
|---|---|---|
| Market Cap | $17.30B | 5/25 |
| P/E Ratio | 72.85x | 1/5 |
| P/B Ratio | 2.39x | 13/23 |
| Dividend Yield | 0.18% | – |
| EPS | $2.08 | – |
| Book Value/Share | $64.78 | – |
| Revenue/Share | $26.09 | – |
| FCF/Share | $5.00 | – |
| Metric | RVTY | Rank |
|---|---|---|
| ROE | 3.3% | 4/21 |
| ROA | 2.0% | 5/22 |
| ROIC | 3.3% | 3/21 |
| Gross Margin | 55.7% | 5/19 |
| Operating Margin | 12.3% | 3/21 |
| Net Margin | 8.2% | 5/20 |
| EBT Margin | 9.0% | 5/22 |
| Tax Rate | 9.0% | – |
| Metric | RVTY | Rank |
|---|---|---|
| Current Ratio | 1.80x | 21/25 |
| Quick Ratio | 1.50x | 18/24 |
| D/E Ratio | 0.67x | 9/24 |
| Financial Leverage | 1.67x | 9/24 |
| Interest Coverage | 1.3x | 6/21 |
| Working Capital | $1.02B | 6/25 |
| Metric | RVTY | Rank |
|---|---|---|
| Operating Cash Flow | $628M | 4/24 |
| Free Cash Flow | $558M | 4/20 |
| Capital Spending | -$70M | 14/20 |
| OCF Growth YoY | 7.4% | 5/12 |
| FCF Growth YoY | 11.0% | 5/11 |
| FCF/Sales | 19.2% | 4/19 |
| CapEx/Sales | 2.4% | 11/19 |
| Metric | RVTY | Rank |
|---|---|---|
| Asset Turnover | 0.24x | 17/21 |
| Receivables Turnover | 4.1x | 18/19 |
| Inventory Turnover | 3.4x | 5/19 |
| Fixed Assets Turnover | 6.4x | 7/21 |
| Days Sales Outstanding | 89 days | 2/19 |
| Days Inventory | 107 days | 15/19 |
| Payables Period | 47 days | 10/18 |
| Cash Conversion Cycle | 149 days | 11/17 |
| Metric | RVTY | Rank |
|---|---|---|
| Total Revenue | $2.91B | 7/21 |
| Operating Income | $358M | 3/21 |
| Net Income | $237M | 4/22 |
| R&D Expense | $216M | 8/21 |
| SG&A Expense | $1.03B | 6/20 |
| Cost of Goods Sold | $1.29B | 6/19 |
| Metric | RVTY | Rank |
|---|---|---|
| Dividends Per Share | $0.28 | – |
| Payout Ratio | 13.5% | – |
| Shares Outstanding | 112M | – |
| Total Current Assets | $2.30B | 19.1% of assets |
| Cash & Short-term Investments | $1.02B | 8.5% of assets |
| Accounts Receivable | $709M | 5.9% of assets |
| Inventory | $378M | 3.1% of assets |
| Total Liabilities | $4.82B | 40.0% of assets |
| Short-term Debt | $1.11B | 9.2% of assets |
Companies classified under the same SEC industry code as Revvity, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| RVTY Revvity, Inc. | ▼ | $17.30B |
| A Agilent Technologies, Inc. | ▼ | $48.40B |
| WAT Waters Corp /De/ | ▲ | $42.45B |
| ILMN Illumina, Inc. | ▶ | $40.95B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.02B |
| AVTR Avantor, Inc. | ▶ | $10.62B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.73B |
| TXG 10x Genomics, Inc. | ▲ | $9.35B |
| BRKR Bruker Corp | ▲ | $8.56B |
| ALMR Alamar Biosciences, Inc. | ▶ | $1.63B |
| CTKB Cytek Biosciences, Inc. | ▲ | $695M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $637M |
| MASS 908 Devices Inc. | ▲ | $500M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $275M |
| EYPT Eyepoint, Inc. | ▲ | $265M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $261M |
| QTRX Quanterix Corp | ▲ | $149M |
| SEER Seer, Inc. | ▶ | $119M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $44M |
| PRPO Precipio, Inc. | ▲ | $40M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $11M |
| SCND Scientific Industries Inc | ▲ | $8M |
<?xml encoding="utf-8" ?> Revvity Inc. RVTY drew new bullish coverage Monday as William Blair initiated the stock with an Outperform rating, arguing that artificial intelligence could become a net ...
Revvity, Inc. (NYSE: RVTY), a prominent player in the healthcare sector, particularly in diagnostics and research, continues ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Our AI ranks Revvity, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
A per-ticker accuracy statistic for RVTY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Revvity, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
25 issuers in our coverage, RVTY included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Avantor, Inc. (AVTR), Bio-Rad Laboratories, Inc. (BIO).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.